On October 18, Eli Lilly announced a definitive agreement to acquire Akouos. Under the terms of the deal, Eli Lilly will acquire all outstanding shares
On October 17, Milestone Pharmaceuticals announced positive data from the Phase III RAPID study of the inhaled calcium channel blocker Etripamil in the treatment of
On October 13, Relmada Therapeutics announced that its REL-1017 for the treatment of major depressive disorder (MDD) failed to meet the primary endpoint of improvement
Lung cancer is one of the leading causes of cancer deaths worldwide. Small cell lung cancer (SCLC) is a highly aggressive and lethal malignancy that
Merck announced that the Phase III STELLAR clinical study of sotatercept in pulmonary arterial hypertension (PAH) achieved positive top-line results, meeting the primary endpoint and
On October 12, Rongchang Bio announced that Taitacept (R&D code: RC18, trade name: Taiai®) was granted orphan drug designation by the U.S. Food and Drug
On October 10, Daré Bioscience announced that the FDA granted an Investigational Device Exemption (IDE) application allowing it to conduct a pivotal Phase III clinical
On October 10, according to foreign media reports, the AstraZeneca/Oxford University Intranasal COVID-19 vaccine did not work well in early studies. The results showed that
On October 10, Merck announced that its potential “first-in-class” therapy sotatercept met the primary clinical endpoint in a Phase 3 clinical trial for the treatment
On October 6, Allogene announced the initiation of the Phase II ALPHA2 trial of the investigational allogeneic CAR T therapy ALLO-501A for the treatment of
Oramed Subsidiary Oravax Reports Positive Preliminary Phase 1 Data for its Oral Covid-19 Vaccine -Primary and secondary endpoints of safety and immunogenicity met -Oral vaccine
On October 4, the U.S. Department of Health and Human Services (HHS) announced that it was purchasing roprostim from Amgen to respond to radiological and
